Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603623 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
A Phase 2 study, sponsored by Biohaven Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 647
- Enrollment target
NCT06603623: Completed Phase 2 study, sponsored by Biohaven Therapeutics.
NCT06603623 is a Phase 2 study that has completed, run by Biohaven Therapeutics. The registered enrollment target is 647 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (386% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06603623, a Phase 2 study, has completed, sponsored by Biohaven Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 647 participants
- Enrollment target
Study Summary
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
Primary Outcome
Pain levels are assessed on a 4-point scale (none, mild, moderate, severe) using the electronic diary (eDiary). Pain freedom is defined as pain level of none. Coprimary endpoints will be tested hierarachically by dose
Interventions
- DRUG Placebo
- DRUG BHV-2100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 647 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2025-03-28 |
| Phase | Phase 2 |
What the finished NCT06603623 record still lists
NCT06603623 is an interventional study that assigns participants to a tested intervention. The registered 647 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (386% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06603623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06603623 about?
NCT06603623 is a clinical study titled "Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine". This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
What is the current status of trial NCT06603623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 647 participants. The study started on 2024-10-10. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT06603623?
The interventions under investigation include: Placebo (DRUG), BHV-2100 (DRUG).
Who is sponsoring clinical trial NCT06603623?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06603623's enrollment target sits among peer trials
647 50th of 2000 higher than 1,951 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07027306 · 648 participants
The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures
- NCT07164456 · 648 participants · NA
Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI